Compare Autodesk Inc (ADSK) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autodesk Inc vs Novo Nordisk A/S — how do they compare? Autodesk Inc trades at $248.76 (market cap $53.12B), while Novo Nordisk A/S trades at $46.44 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 3.9× Autodesk Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Autodesk Inc pays none. Which is the better fit depends on your goals.
| ADSK | NVO | |
|---|---|---|
Market Cap | $53.12B | $207.85B |
Sector | Technology | Health |
52-Week High | $326.79 | $63.98 |
52-Week Low | $187.72 | $35.29 |
Enterprise Value | $52.92B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Autodesk (ADSK) trades at $249.55, down 2.55% today, but maintains a strong fundamental profile with robust earnings beats, including Q1 2026 EPS of $2.99 versus $2.84 expected. The stock exhibits a bullish technical trend with moving averages supporting upside, though RSI levels indicate potential overbought conditions. Revenue growth is steady, projected to reach $7.5B in 2026, with a high net income margin of 19.49% in 2025.
The outlook remains positive given analyst consensus favoring Buy ratings (74.51%) and a $302.23 price target, implying significant upside. Key risks include competitive pressures in design software and reliance on enterprise spending cycles. Continued execution on AI investments and margin expansion are critical for sustaining valuation multiples.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Autodesk Inc
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
